SMO and cancer: Erismodegib (also known as sonidegib and Odomzo®, East Hanover, NJ, USA) is an orally bioavailable SMO antagonist created by Novartis that has been shown to induce cell cycle arrest and apoptosis in a variety of cancer cell lines [87].